NORTH AMERICA CRISPR MARKET FORECAST 2018-2026
KEY FINDINGS
The North America CRISPR market was valued to be at $ 224 million in 2017. Over the forecast period of 2018-2026, the market is projected to witness a CAGR of 36.44%, collecting a net total of $3636 million by the end of 2026.
MARKET INSIGHTS
North America accounted for the maximum revenue share in the global CRISPR market. Pharmaceutical industries are the key end-users of the CRISPR in this region. Also, the growing market for stem cell therapy is considerably fuelling the demand for CRISPR market. Increasing grant for orphan drug status for stem cell therapeutics by the FDA, an extensive government funding and the presence of major leading market companies in the region are some of the important factors propelling the growth of this market. The US is considered to be a lucrative market in this region, driven by increased healthcare spending. The Canadian Budget 2016, too, played a significant role in the development of CRISPR market in the region by funding various research activities of genomics, drug discovery and stem cell research.
COMPETITIVE INSIGHTS
Noted players in this market include Crispr Therapeutics Ag, Novartis International Ag, Integrated DNA Technologies (IDT), Editas Medicine, Genscript, Cellectis Bioresearch Sas, Precision Biosciences, Transposagen Biopharmaceuticals Inc, Sigma-Aldrich (Merck), Intellia Therapeutics Inc, Origene Technologies Inc, and Venture Capital Funding.
The North America CRISPR market was valued to be at $ 224 million in 2017. Over the forecast period of 2018-2026, the market is projected to witness a CAGR of 36.44%, collecting a net total of $3636 million by the end of 2026.
MARKET INSIGHTS
North America accounted for the maximum revenue share in the global CRISPR market. Pharmaceutical industries are the key end-users of the CRISPR in this region. Also, the growing market for stem cell therapy is considerably fuelling the demand for CRISPR market. Increasing grant for orphan drug status for stem cell therapeutics by the FDA, an extensive government funding and the presence of major leading market companies in the region are some of the important factors propelling the growth of this market. The US is considered to be a lucrative market in this region, driven by increased healthcare spending. The Canadian Budget 2016, too, played a significant role in the development of CRISPR market in the region by funding various research activities of genomics, drug discovery and stem cell research.
COMPETITIVE INSIGHTS
Noted players in this market include Crispr Therapeutics Ag, Novartis International Ag, Integrated DNA Technologies (IDT), Editas Medicine, Genscript, Cellectis Bioresearch Sas, Precision Biosciences, Transposagen Biopharmaceuticals Inc, Sigma-Aldrich (Merck), Intellia Therapeutics Inc, Origene Technologies Inc, and Venture Capital Funding.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. DESIGN TOOLS ARE GROWING AT A FASTER RATE IN TERMS OF PRODUCT
3.2.2. PHARMA COMPANIES ARE GROWING RAPIDLY
3.2.3. GENOME EDITING TO HOLD THE LARGEST SHARE
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. INCREASING DEMAND FOR DRUG DISCOVERY
4.1.2. LATE PREGNANCIES LEADING TO BIRTH DISORDERS
4.1.3. SYNTHETIC GENES LEAD THE WAY
4.1.4. AGING GENETIC DISORDERS
4.1.5. INVESTMENT IN PATH BREAKING RESEARCH TECHNOLOGY
4.1.6. CHANGING LIFESTYLES
4.2. RESTRAINTS
4.2.1. POSSIBLE MISUSE OF CRISPR GENE EDITING TOOL
4.2.2. LACK OF AWARENESS
4.3. OPPORTUNITIES
4.3.1. GENOME SURGERY TO REWRITE GENETIC DISORDERS
4.4. CHALLENGES
4.4.1. PROTECTION OF PATENT
4.4.2. ALTERNATE TECHNOLOGIES
4.4.3. LACK OF HEALTHCARE BUDGETS IN DEVELOPING COUNTRIES
5. MARKET SEGMENTATION
5.1. MARKET BY PRODUCT 2018-2026
5.1.1. DESIGN TOOLS
5.1.2. PLASMIDS AND VECTORS
5.1.3. CAS9 NUCLEASE AND GRNA
5.1.4. DELIVERY SYSTEM
5.2. MARKET BY END USER 2018-2026
5.2.1. BIOTECHNOLOGY FIRMS
5.2.2. PHARMACEUTICAL COMPANIES
5.2.3. ACADEMIC INSTITUTES
5.2.4. RESEARCH FOUNDATION
5.3. MARKET BY APPLICATION 2018-2026
5.3.1. GENOME EDITING
5.3.2. GENETIC ENGINEERING
5.3.3. GRNA DATABASE/GENE LIBRARY
5.3.4. CRISPR PLASMID
5.3.5. HUMAN STEM CELLS
5.3.6. GENETICALLY MODIFIED ORGANISMS/CROPS
5.3.7. CELL LINE ENGINEERING
6. KEY ANALYTICS
6.1. PORTER’S 5 FORCE MODEL
6.1.1. THREATS OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. MARKET ETYMOLOGY
6.3. SUPPLY CHAIN ANALYSIS
6.4. REGULATORY FRAMEWORK
6.5. VALUE CHAIN ANALYSIS
6.6. KEY BUYING CRITERIA
6.7. PATENT ANALYSIS
6.8. 360 DEGREE ANALYSIS
6.9. STRATEGIC RECOMMENDATION AND CONCLUSION
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
7.1.3. RONA (REST OF NORTH AMERICA)
8. COMPANY PROFILE
8.1. COMPETITIVE ANALYSIS
8.1.1. TOP 5 COMPANIES
8.1.2. MERGERS AND ACQUISITION
8.1.3. PARTNERSHIPS AND COLLABORATIONS
8.1.4. INNOVATIONS
8.1.5. VENTURE CAPITAL FUNDING
8.2. EDITAS MEDICINE
8.3. CRISPR THERAPEUTICS AG
8.4. HORIZON DISCOVERY PLC.
8.5. SIGMA-ALDRICH (MERCK)
8.6. GENSCRIPT
8.7. SANGAMO BIOSCIENCES INC.
8.8. LONZA GROUP AG
8.9. INTEGRATED DNA TECHNOLOGIES (IDT)
8.10. NEW ENGLAND BIOLABS INC
8.11. ORIGENE TECHNOLOGIES INC
8.12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
8.13. THERMO FISHER SCIENTIFIC
8.14. CARIBOU BIOSCIENCES INC.
8.15. PRECISION BIOSCIENCES
8.16. CELLECTIS BIORESEARCH SAS
8.17. INTELLIA THERAPEUTICS INC
8.18. NOVARTIS INTERNATIONAL AG
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. DESIGN TOOLS ARE GROWING AT A FASTER RATE IN TERMS OF PRODUCT
3.2.2. PHARMA COMPANIES ARE GROWING RAPIDLY
3.2.3. GENOME EDITING TO HOLD THE LARGEST SHARE
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. INCREASING DEMAND FOR DRUG DISCOVERY
4.1.2. LATE PREGNANCIES LEADING TO BIRTH DISORDERS
4.1.3. SYNTHETIC GENES LEAD THE WAY
4.1.4. AGING GENETIC DISORDERS
4.1.5. INVESTMENT IN PATH BREAKING RESEARCH TECHNOLOGY
4.1.6. CHANGING LIFESTYLES
4.2. RESTRAINTS
4.2.1. POSSIBLE MISUSE OF CRISPR GENE EDITING TOOL
4.2.2. LACK OF AWARENESS
4.3. OPPORTUNITIES
4.3.1. GENOME SURGERY TO REWRITE GENETIC DISORDERS
4.4. CHALLENGES
4.4.1. PROTECTION OF PATENT
4.4.2. ALTERNATE TECHNOLOGIES
4.4.3. LACK OF HEALTHCARE BUDGETS IN DEVELOPING COUNTRIES
5. MARKET SEGMENTATION
5.1. MARKET BY PRODUCT 2018-2026
5.1.1. DESIGN TOOLS
5.1.2. PLASMIDS AND VECTORS
5.1.3. CAS9 NUCLEASE AND GRNA
5.1.4. DELIVERY SYSTEM
5.2. MARKET BY END USER 2018-2026
5.2.1. BIOTECHNOLOGY FIRMS
5.2.2. PHARMACEUTICAL COMPANIES
5.2.3. ACADEMIC INSTITUTES
5.2.4. RESEARCH FOUNDATION
5.3. MARKET BY APPLICATION 2018-2026
5.3.1. GENOME EDITING
5.3.2. GENETIC ENGINEERING
5.3.3. GRNA DATABASE/GENE LIBRARY
5.3.4. CRISPR PLASMID
5.3.5. HUMAN STEM CELLS
5.3.6. GENETICALLY MODIFIED ORGANISMS/CROPS
5.3.7. CELL LINE ENGINEERING
6. KEY ANALYTICS
6.1. PORTER’S 5 FORCE MODEL
6.1.1. THREATS OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. MARKET ETYMOLOGY
6.3. SUPPLY CHAIN ANALYSIS
6.4. REGULATORY FRAMEWORK
6.5. VALUE CHAIN ANALYSIS
6.6. KEY BUYING CRITERIA
6.7. PATENT ANALYSIS
6.8. 360 DEGREE ANALYSIS
6.9. STRATEGIC RECOMMENDATION AND CONCLUSION
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
7.1.3. RONA (REST OF NORTH AMERICA)
8. COMPANY PROFILE
8.1. COMPETITIVE ANALYSIS
8.1.1. TOP 5 COMPANIES
8.1.2. MERGERS AND ACQUISITION
8.1.3. PARTNERSHIPS AND COLLABORATIONS
8.1.4. INNOVATIONS
8.1.5. VENTURE CAPITAL FUNDING
8.2. EDITAS MEDICINE
8.3. CRISPR THERAPEUTICS AG
8.4. HORIZON DISCOVERY PLC.
8.5. SIGMA-ALDRICH (MERCK)
8.6. GENSCRIPT
8.7. SANGAMO BIOSCIENCES INC.
8.8. LONZA GROUP AG
8.9. INTEGRATED DNA TECHNOLOGIES (IDT)
8.10. NEW ENGLAND BIOLABS INC
8.11. ORIGENE TECHNOLOGIES INC
8.12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
8.13. THERMO FISHER SCIENTIFIC
8.14. CARIBOU BIOSCIENCES INC.
8.15. PRECISION BIOSCIENCES
8.16. CELLECTIS BIORESEARCH SAS
8.17. INTELLIA THERAPEUTICS INC
8.18. NOVARTIS INTERNATIONAL AG
LIST OF TABLES
TABLE 1 NORTH AMERICA CRISPR MARKET 2018-2026 ($ MILLIONS)
TABLE 2 VARIOUS INITIATIVES AND POLICIES UNDERTAKEN BY THE GOVERNMENT IN HEALTHCARE SECTOR
TABLE 3 RISING PUBLIC HEALTH AND LONG-TERM CARE EXPENDITURE OVER THE NEXT DECADES (%)
TABLE 4 MAJOR CONCERNS RELATED TO GENETIC ENGINEERING
TABLE 5 NORTH AMERICA CRISPR PRODUCT MARKET SHARE 2018-2026 ($ MILLIONS)
TABLE 6 TOOLS NAME AND THEIR PROVIDERS
TABLE 7 NORTH AMERICA CRISPR MARKET IN DESIGN TOOLS 2018-2026 ($ MILLIONS)
TABLE 8 NORTH AMERICA CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
TABLE 9 NORTH AMERICA CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
TABLE 10 NORTH AMERICA CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
TABLE 11 NORTH AMERICA CRISPR MARKET IN END USER 2018-2026 ($ MILLIONS)
TABLE 12 NORTH AMERICA CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
TABLE 13 NORTH AMERICA CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLIONS)
TABLE 14 NORTH AMERICA CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
TABLE 15 NORTH AMERICA CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
TABLE 16 NORTH AMERICA CRISPR MARKET BY APPLICATION 2018-2026 ($ MILLIONS)
TABLE 17 NORTH AMERICA CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
TABLE 18 NORTH AMERICA CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 19 NORTH AMERICA CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
TABLE 20 NORTH AMERICA CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
TABLE 21 NORTH AMERICA CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
TABLE 22 NORTH AMERICA CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
TABLE 23 NORTH AMERICA CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 24 NORTH AMERICA CRISPER MARKET 2018-2026 ($ MILLION)
TABLE 25 FUNDS ALLOCATED FOR RESEARCH ACTIVITIES IN BUDGET 2016
TABLE 26 GM CROPS GROWN IN CANADA
LIST OF FIGURE
FIGURE 1 FATALITIES INCREASING DUE TO LIFESTYLE ORIENTED DISEASES (IN THOUSAND)
FIGURE 2 REASON FOR OUTSOURCING DRUG DISCOVERY PROJECTS
FIGURE 3 NORTH AMERICA CRISPR MARKET IN DESIGN TOOLS MARKET SHARE 2018-2026 ($ MILLIONS)
FIGURE 4 NORTH AMERICA CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
FIGURE 5 NORTH AMERICA CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
FIGURE 6 NORTH AMERICA CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
FIGURE 7 NORTH AMERICA CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
FIGURE 8 NORTH AMERICA CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLION)
FIGURE 9 NORTH AMERICA CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
FIGURE 10 NORTH AMERICA CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
FIGURE 11 NORTH AMERICA CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
FIGURE 12 NORTH AMERICA CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 13 NORTH AMERICA CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
FIGURE 14 NORTH AMERICA CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
FIGURE 15 NORTH AMERICA CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
FIGURE 16 NORTH AMERICA CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
FIGURE 17 NORTH AMERICA CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 18 VALUE CHAIN ANALYSIS
FIGURE 19 NORTH AMERICA CRISPR MARKET SHARE 2016
FIGURE 20 NORTH AMERICA CRISPER MARKET 2018-2026 ($ MILLION)
FIGURE 21 ADOPTION OF GMO CROPS IN THE U.S. IN 2016
FIGURE 22 U.S. CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 23 REASONS FOR ADOPTING GENETICALLY ENGINEERED CROP (BT COTTON)
FIGURE 24 GM CROPS GROWN IN CANADA
FIGURE 25 CANADA CRISPER MARKET 2018-2026 ($ MILLION)
FIGURE 26 RONA CRISPER MARKET 2018-2026($MILLION)
FIGURE 27 CRISPR MARKET COMPANIES SHARE 2016
COMPANIES MENTIONED
2. EDITAS MEDICINE
3. CRISPR THERAPEUTICS AG
4. HORIZON DISCOVERY PLC.
5. SIGMA-ALDRICH (MERCK)
6. GENSCRIPT
7. SANGAMO BIOSCIENCES INC.
8. LONZA GROUP AG
9. INTEGRATED DNA TECHNOLOGIES (IDT)
10. NEW ENGLAND BIOLABS INC
11. ORIGENE TECHNOLOGIES INC
12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
13. THERMO FISHER SCIENTIFIC
14. CARIBOU BIOSCIENCES INC.
15. PRECISION BIOSCIENCES
16. CELLECTIS BIORESEARCH SAS
17. INTELLIA THERAPEUTICS INC
18. NOVARTIS INTERNATIONAL AG
TABLE 1 NORTH AMERICA CRISPR MARKET 2018-2026 ($ MILLIONS)
TABLE 2 VARIOUS INITIATIVES AND POLICIES UNDERTAKEN BY THE GOVERNMENT IN HEALTHCARE SECTOR
TABLE 3 RISING PUBLIC HEALTH AND LONG-TERM CARE EXPENDITURE OVER THE NEXT DECADES (%)
TABLE 4 MAJOR CONCERNS RELATED TO GENETIC ENGINEERING
TABLE 5 NORTH AMERICA CRISPR PRODUCT MARKET SHARE 2018-2026 ($ MILLIONS)
TABLE 6 TOOLS NAME AND THEIR PROVIDERS
TABLE 7 NORTH AMERICA CRISPR MARKET IN DESIGN TOOLS 2018-2026 ($ MILLIONS)
TABLE 8 NORTH AMERICA CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
TABLE 9 NORTH AMERICA CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
TABLE 10 NORTH AMERICA CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
TABLE 11 NORTH AMERICA CRISPR MARKET IN END USER 2018-2026 ($ MILLIONS)
TABLE 12 NORTH AMERICA CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
TABLE 13 NORTH AMERICA CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLIONS)
TABLE 14 NORTH AMERICA CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
TABLE 15 NORTH AMERICA CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
TABLE 16 NORTH AMERICA CRISPR MARKET BY APPLICATION 2018-2026 ($ MILLIONS)
TABLE 17 NORTH AMERICA CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
TABLE 18 NORTH AMERICA CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 19 NORTH AMERICA CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
TABLE 20 NORTH AMERICA CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
TABLE 21 NORTH AMERICA CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
TABLE 22 NORTH AMERICA CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
TABLE 23 NORTH AMERICA CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 24 NORTH AMERICA CRISPER MARKET 2018-2026 ($ MILLION)
TABLE 25 FUNDS ALLOCATED FOR RESEARCH ACTIVITIES IN BUDGET 2016
TABLE 26 GM CROPS GROWN IN CANADA
LIST OF FIGURE
FIGURE 1 FATALITIES INCREASING DUE TO LIFESTYLE ORIENTED DISEASES (IN THOUSAND)
FIGURE 2 REASON FOR OUTSOURCING DRUG DISCOVERY PROJECTS
FIGURE 3 NORTH AMERICA CRISPR MARKET IN DESIGN TOOLS MARKET SHARE 2018-2026 ($ MILLIONS)
FIGURE 4 NORTH AMERICA CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
FIGURE 5 NORTH AMERICA CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
FIGURE 6 NORTH AMERICA CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
FIGURE 7 NORTH AMERICA CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
FIGURE 8 NORTH AMERICA CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLION)
FIGURE 9 NORTH AMERICA CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
FIGURE 10 NORTH AMERICA CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
FIGURE 11 NORTH AMERICA CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
FIGURE 12 NORTH AMERICA CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 13 NORTH AMERICA CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
FIGURE 14 NORTH AMERICA CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
FIGURE 15 NORTH AMERICA CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
FIGURE 16 NORTH AMERICA CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
FIGURE 17 NORTH AMERICA CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 18 VALUE CHAIN ANALYSIS
FIGURE 19 NORTH AMERICA CRISPR MARKET SHARE 2016
FIGURE 20 NORTH AMERICA CRISPER MARKET 2018-2026 ($ MILLION)
FIGURE 21 ADOPTION OF GMO CROPS IN THE U.S. IN 2016
FIGURE 22 U.S. CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 23 REASONS FOR ADOPTING GENETICALLY ENGINEERED CROP (BT COTTON)
FIGURE 24 GM CROPS GROWN IN CANADA
FIGURE 25 CANADA CRISPER MARKET 2018-2026 ($ MILLION)
FIGURE 26 RONA CRISPER MARKET 2018-2026($MILLION)
FIGURE 27 CRISPR MARKET COMPANIES SHARE 2016
COMPANIES MENTIONED
2. EDITAS MEDICINE
3. CRISPR THERAPEUTICS AG
4. HORIZON DISCOVERY PLC.
5. SIGMA-ALDRICH (MERCK)
6. GENSCRIPT
7. SANGAMO BIOSCIENCES INC.
8. LONZA GROUP AG
9. INTEGRATED DNA TECHNOLOGIES (IDT)
10. NEW ENGLAND BIOLABS INC
11. ORIGENE TECHNOLOGIES INC
12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
13. THERMO FISHER SCIENTIFIC
14. CARIBOU BIOSCIENCES INC.
15. PRECISION BIOSCIENCES
16. CELLECTIS BIORESEARCH SAS
17. INTELLIA THERAPEUTICS INC
18. NOVARTIS INTERNATIONAL AG
